In a formal regulatory filing dated June 30, 2025, Vivo Bio Tech Limited has announced that Mrs. Kunda Kalpana, who served as a Non-Executive Independent Director, has completed her 5-year tenure with the company as of the end of the day on June 29, 2025. The disclosure has been made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further aligned with the SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

The Board of Directors and management team of Vivo Bio Tech expressed deep appreciation and gratitude to Mrs. Kalpana for her dedicated service, strategic insights, and valuable contributions during her tenure on the Board. As a Non-Executive Independent Director, Mrs. Kalpana played an instrumental role in enhancing the company’s governance framework and ensuring transparency in corporate practices.

Background of the Disclosure:

Vivo Bio Tech Limited, listed on BSE under the Scrip Code: 511509, is compliant with regulatory norms that mandate timely disclosures related to the appointment, resignation, or cessation of directors. The cessation of an Independent Director upon completion of their term is classified as a material event and must be disclosed under SEBI Regulation 30, along with the required annexures.

The filing also includes Annexure – A, providing the structured details required under the applicable SEBI regulations, which outlines:

• Name and designation of the Director: Mrs. Kunda Kalpana, Non-Executive Independent Director.

• Reason for change: Cessation upon completion of the 5-year term.

• Effective date: June 29, 2025.

• Other requirements, such as relationships with directors and additional profile details, are marked as not applicable, since it is not a new appointment.

About Mrs. Kunda Kalpana’s Tenure:

During her tenure as an Independent Director, Mrs. Kalpana contributed significantly to the company’s strategic direction, compliance mechanisms, and corporate governance initiatives. Her insights and experience were particularly valuable in risk management, ethical oversight, and sustainability frameworks, key elements that align with the evolving expectations of regulators and stakeholders.

Her role extended beyond boardroom deliberations as she actively participated in the Audit Committee, Nomination and Remuneration Committee, and other governance sub-committees of the company. She is recognized for her balanced decision-making approach, and independent judgment, both of which are central tenets of an effective Independent Director under SEBI norms.

Corporate Governance at Vivo Bio Tech:

Vivo Bio Tech is known for maintaining a strong corporate governance culture, which includes periodic board assessments, clear separation of roles, and active engagement with shareholders. The conclusion of an Independent Director’s term and its timely intimation to the exchange reflects the company’s adherence to best governance practices and regulatory transparency.

The company has also demonstrated commitment toward complying with recent SEBI updates, including circulars that seek better disclosures on board composition, diversity, and rotation of independent board members. The June 30, 2025 disclosure is a part of the company’s ongoing efforts to stay aligned with such evolving standards.

What Happens Next:

As of this filing, Vivo Bio Tech has not yet disclosed the appointment of a new Independent Director in place of Mrs. Kalpana. However, as per SEBI (LODR) Regulations, listed companies are required to maintain the composition of the Board, which includes ensuring the minimum number of independent directors, especially for companies with executive chairpersons or specific board strength.

It is expected that the company will soon initiate the nomination process to fill the vacancy and maintain regulatory compliance. Any such appointment would be subject to Board approval and will be intimated to the exchange in due course, along with the details required under applicable circulars such as:

• NSE Circular no. NSE/CML/2018/24

• BSE Circular no. LIST/COMP/14/2018-19

Regulatory References:

This disclosure refers specifically to:

• Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

• SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

• BSE Circular LIST/COMP/14/2018-19 dated June 20, 2018

• NSE Circular NSE/CML/2018/24 dated June 20, 2018

Conclusion:

With the formal completion of Mrs. Kunda Kalpana’s tenure as an Independent Director, Vivo Bio Tech Limited reaffirms its commitment to sound corporate governance and regulatory integrity. Stakeholders, including investors and corporate analysts, will now await updates on the potential appointment of a new Independent Director to ensure continuity and balance in the Board’s composition.

This announcement represents yet another example of how listed entities are following structured governance mechanisms laid out by Indian regulators, ensuring that all material information is disseminated promptly and transparently.

The Upcoming IPOs in this week and coming weeks are Chemkart India, Meta Infotech, Happy Square Outsourcing Services, Travel Food Services, Cryogenic, Crizac.

The Current active IPO are Silky Overseas, Vandan Foods, Pushpa Jewellers, Cedaar Textile, Marc Loire Fashions, Neetu Yoshi, Adcounty Media India, Moving Media Entertainment, Valencia India, PRO FX Tech, Ace Alpha Tech, Indogulf Cropsciences.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.